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1. Introduction
With the global evolution of organ transplantation in humans a new class of patients with
special problems related to opportunistic infections after transplantation has appeared [1,
2 ].Some of these challenges infections with members of the herpesvirus family. Among these
viruses, human cytomegalovirus (HCMV) often affects immunocompromised patients,
HCMV can be reactivated by immunosuppression and cause significant morbidity and
mortality [3,4]. In the postoperative period, HCMV infection can result in serious complica‐
tions in patients who received grafts by modulating the immune response [5]. However in
immunocompetent individuals cytomegalovirus infection can be asymptomatic or cause
symptoms similar to infectious mononucleosis syndrome, such as lymphadenopathy, fever,
rash, malaise, arthralgia, hepatomegaly and splenomegaly [6].
This chapter presents the main clinical and epidemiological aspects related to cytomegalovirus
infection and the importance of detection in liver transplant recipients.
2. Cytomegalovirus history
The discovery of HCMV began in 1881 when the histological effects of infection were observed
in the kidney of a newborn child. In 1904, Ribbert identified the causative agent of "cytomegalic
inclusion disease", whose name derives from the characteristic cytopathic effect, represented
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by increases in cell volume and intracellular cytoplasmic inclusions in infected tissues [7]. In
1881 and 1921 similar cell characteristics were reported by Goodpasture and Talbot in a fatal
case associated with this virus involving lung, liver and kidney from a newborn child [8].
The first experimental evidence of the likely etiologic agent of "cytomegalic inclusion disease"
was proposed by Cole and Kuttner in 1926, when they demonstrated the transmission of the
disease in guinea pigs and suggested that this agent possessed characteristics of viral infection
and was species-specific. Wolbach and Farber (1932) demonstrated the first evidence that the
salivary gland virus was commonly involved and showed typical cytomegalic cells were found
in 12% of children. In 1954, using the salivary infection mouse model, Smith isolated the virus
in tissue culture [9].
In 1970 study groups were organized to evaluate the impact of infection in immunocompro‐
mised people and through this to propose infection control strategies. In the 1980s the control
measures of CMV began with antiviral agents and immunological interventions [10].
3. Structure features and replication engine
CMV has an ultrastructure similar to other herpesviruses with four structural elements: an
electron-dense core, an icosahedral symmetry capsid, a tegument occupying space between
the capsid and an envelope steeped in glycoproteins and membrane proteins [11].
CMV carries a double-stranded DNA containing approximately 240 kb linear bases [12]
encoding 33 structural proteins and an indefinite number of non-structural proteins, some of
which are antigenic. The genome can be divided into two segments, designated as long
component (L) and short (S) defined by repetitive sequence terminals (RT). The CMV has a
complex genome due to the acquisitions of host genes and the duplication of viral genes [13].
It is a very thermolabile virus and its average life at 37 ° C is only 45 minutes, totally inactivated
at 56 º C for 30 minutes [14].
During natural infection, viral replication can occur in epithelial, endothelial and muscle
mesenchymal cells, hepatocytes, granulocytes and macrophages [15, 16]. In vivo studies with
cells from immunocompetent and immunosuppressed patients show that CMV can commonly
be isolated from polymorphonuclear leukocytes [17], which may represent an important
replication site [14,16]. Variants of CMV are found in mice, monkeys and guinea pigs, but these
strains are species-specific and do not infect humans [14].
The CMV replication mechanism occurs in three distinct stages, similar to other herpesviruses.
The early phase occurs when the virus adheres to the host cell membrane (with the envelope
loss and penetration into the cell), in the intermediate phase the gene expression and genome
replication occur, and in the late phase, there is the assembly and release of new viral particles
[16-18].
The “early” phase begins when surface proteins of the virion adhere to specific protein
receptors on the cell surface through non-covalent bonds. The viral particles penetrate by
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endocytosis, entering pinocytic vesicles in which the envelope loss process is started, favored
by a low pH. The rupture of the vesicles or fusion of the virus with the outer layer of the vesicle
membrane deposits the core of the virus in the cell cytoplasm [13].
The intermediate phase lasts 24 hours, characterized by transcription and replication of viral
DNA. The first step of viral gene expression is the synthesis of mRNA via host RNA poly‐
merase inside the core. The mRNA is translated by the host ribosomes into early and late viral
proteins. The early proteins are enzymes required for viral genome replication [19]. The late
proteins include a polymerase replicating the viral genome [13].
In the late phase, viral particles newly formed are grouped together within the capsid and
begin the process of budding, during which the nucleocapsid adheres to specific sites of the
membrane and interacts with the protein matrix. At this point, a process of evagination occurs
and an enveloped particle flows from the membrane surface [13].
4. Transmission and epidemiology
Infection is defined as seroconversion (an increase of 4 times or more in HCMV antibody titer
in seronegative or seropositive patients), virus circulation in any body fluid such as urine,
nasopharyngeal secretions or blood [7]. CMV infects only the human population and its
transmission occurs both horizontally and vertically and may include oropharyngeal secre‐
tions, vaginal tears, seminal fluid, breast milk, urine, feces and blood [19]. In adulthood the
CMV transmission may occur through heterosexual and homosexual contact, through blood
and blood products and through organ transplantation, the latter being an important route of
transmission [12,19, 20].
About 80% of the population between late childhood and early adolescence is already infected
with CMV [21, 22] and can harbor the virus in various body sites, especially in the salivary
glands and different types of leukocytes. With age the increased prevalence of antibodies is
common. This may not depend on the geographical area, but the socio-economic status may
be important [10, 23- 28]. The seroprevalence of CMV in populations at high socioeconomic
level varies from 40% to 60%, increases after infection of early childhood and approximately
10% to 20% of children have their first infection episode before puberty [10]. In lower socioe‐
conomic populations the seroprevalence level is higher, ranging from 80% to 100%. In Brazil,
seroprevalence of cytomegalovirus averages 90% in adult populations [28].
5. Clinical manifestations
The clinical course of CMV in immunocompetent individuals may be asymptomatic or may
resemble "Mononucleosis Syndrome" presented by persistent fever, myalgia, pharyngitis,
lymphadenopathy, sweating and hepatosplenomegaly [10,28-34].
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After primary infection, CMV persists in host tissues and may be reactivated to cause disease
– usually in children with congenital infection, organ transplant recipients, cancer patients
undergoing chemotherapy and patients with HIV disease [7,10,29,35].
Among the  complications  caused by  CMV in  transplanted  patients  increased  long-term
mortality and worsening graft survival are common [35-37]. Clinical disease caused by CMV
is  expressed  by  fever,  malaise,  myalgia,  leukopenia  (WBC  less  than  4.0000/mm3),  in‐
creased transaminases (hepatitis), pulmonary (pneumonitis) and/or gastrointestinal (colitis,
gastritis, esophagitis) and fever being the most common manifestation, which can also occur
with  neurological  symptomatology  compatible  with  encephalitis  but  these  are  rarer
[29,38,39].
Clinical disease may reflect
1. Primary infection, when it occurs in patients previously seronegative;
2. Secondary infection occurs when the reactivation of latent infection or superinfection;
3. Tertiary infection by reinfection by other strains of the virus [7].
The source of infection for both primary infection and superinfection is may include graft and
blood transfusions. Immunosuppression may cause reactivation of CMV [40]. About two
thirds of patients with primary infection are symptomatic, less than 20% in viral reactivation
have symptoms and about 40% of reinfected individuals have symptoms attributable to CMV
[10]. When primary infection occurs after transplantation the clinical impact is significant [41].
This is most common following allocation of grafts from donors with positive serology to
seronegative recipients [42]. Immunosuppressive drugs such as azathioprine and cyclosporine
have been implicated in the facilitation of CMV disease [7].
Diagnostic criteria include clinical signs known to be caused by this virus [43,44]. In liver
transplant patients with active CMV infection, about 80% will develop clinical manifesta‐
tions of the disease and the rate may be higher when the recipient is seronegative and a
donor is  seropositive [44].  CMV infection is  an independent risk factor for the develop‐
ment  with  opportunistic  infections,  as  well  as  graft  rejection  [7].  The  evidence  of  viral
replication and clinical symptoms in transplant occurs mainly during the 1st to 4th month
post-transplant.
The most common clinical manifestations are interstitial pneumonia, esophagitis, gastritis,
colitis, retinitis, fever and delayed engraftment in bone marrow transplants [29,45]. During
liver transplantation, primary infection tends to be more important as the CMV viremia may
be limited to when virus replication is detected in peripheral blood or significant increase of
specific antibodies without symptoms or viral syndrome presenting fever equal or greater than
38ºC, malaise, leukopenia, atypical lymphocytosis equal or less than 3-5% and thrombocyto‐
penia [14, 37, 42, 45,46].
Antiviral treatment controls the acute manifestation of the disease in most cases, but may not
eradicate the CMV with recurrence reported in 26-31% of solid organ transplant recipients..
[14, 36].
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6. Diagnosis
The diagnosis of CMV infection can be done by serology, polymerase chain reaction (PCR),
culture and viral antigenemia research. Early diagnosis is important as early treatment of
asymptomatic active infection reduces morbidity [24, 31, 46, 47]. The first method of diagnosis
used to identify the CMV was exfoliative cytology. This technique revealed the presence of
large cells which had inclusions within the core, identified as cytomegalic inclusion. Later
methods are more sensitive and specific. These are grouped into seven categories: cytological,
histological, virus isolation, serological identification,, Immunofluorescence, detection of
viral antigens and molecular methods [49, 48]…
Cytopathological techniques: These methods can be performed on tissue and secretions
aspirated material [7,8], but have low sensitivity so they currently have little use in clinical
practice.
Histological Techniques: A method of detecting inclusions by visualization of typical tissue.
The finding of cells with typical inclusions allows often to correlate CMV lesion or dysfunction
of the organ studied. Although this method has low sensitivity, it reveals invasive tissue
disease [7]. The advantages are low cost, simplicity of use and availability of equipment.
Viral Isolation: CMV can be isolated from various biological materials, such as biological
fluids (urine, saliva, blood, cervical secretions, breast milk, tears, semen, feces and washed
aspirates organs) and tissue obtained from biopsies or autopsies [49, 50].
Serological methods: The modern serological methods detect the presence of IgM and IgG [51]
usually by ELISA. This technique does not detect the virus in early stages of infection, as
antibodies are produced by the host only after this phase.
Immunofluorescence (IF): A method that allows an early detection of the virus is immuno‐
fluorescence usually using commercially available antibodies.
Detection of Viral Antigens (antigenemia): Antigenemia offers high sensitivity and specific‐
ity. It is fast, direct and sensitive, and is considered a quantitative technique for viral load [54,
55]. CMV antigenemia is one of the earlier tests with positive results [17, 25, 51- 58] and becomes
positive on average 9-18 days before establishment of the disease. It has been widely used for
the early detection of active infection in organ transplant recipients [17, 24, 25, 36, 56].
The additional advantage of this method is that results can be expressed quantitatively,
allowing observation of the clinical response to treatment [17, 59]. The disadvantage of this
technique is the speed needed to process the collected material without loss of sensitivity - 6
to 8 hours [17]. In patients with neutropenia, this test cannot be performed due to low
granulocyte count. On this situation, molecular assays are used.
Molecular methods
Polymerase chain reaction-PCR: The qualitative PCR is often the first test to detect asympto‐
matic subclinical infection, but specific predictive value is low for the diagnosis of HCMV
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disease. It is not suitable for routine monitoring of patients on treatment [57]…why not???. It
is a quick (4-6 hours), specific and extremely sensitive test but false positives may result from
contamination during the test run. False negative results can also occur due to presence of
inhibitors in the sample [55,60]. The sample type and method of extracting DNA from these
samples must be carefully chosen to avoid this [31,61].
Nested PCR (Polymerase Chain Double): Nested PCR (N-PCR) has been used to increase the
sensitivity and specificity of simple PCR. Here the product of the first PCR, amplified with a
primer pair, is subjected to a new amplification reaction using another pair of primers internal
to the first, the product being then detected by agarose gel electrophoresis [62]. Nested PCR
technique to diagnose CMV infection produces results consistent with classical culture,
reaching 100% specificity and 93% sensitivity in a shorter time frame [63- 66].
Real-time PCR: Real Time PCR amplification (RT PCR) presents high sensitivity and precision.
It has been used for the detection and monitoring of viral load. Its sensitivity and specificity
are directly related to the choice of "primers" and probes, and the accuracy is determined by
the threshold cycle, which is calculated during the exponential phase of the reaction. Formation
of a fluorescently labeled product is monitored at each amplification cycle in a single instru‐
ment generating quantitative results. [58].
7. Treatment
Ganciclovir has been the “gold standard” for treatment of CMV disease although resistance
to this drug has been reported and should be considered in unresponsive patients. Some
studies have focused on genotyping of CMV that could indicate samples that were resistant
to conventional treatment. Inadequate dosing may reduce clinical efficacy and promote
resistance (44)
Antiviral administration is generally initiated in the immediate or early post-transplant period,
and continues for 3 to 6 months. Various antiviral drugs have been used, including acyclovir,
valaciclovir, intravenous ganciclovir, oral valganciclovir or intravenous (IV) ganciclovir, and
valganciclovir. In preventive therapy, laboratory monitoring detects asymptomatic viral
replication and antiviral therapy is initiated to prevent progression to clinical disease. For non
severe CMV disease, oral valganciclovir (900 mg orally every 12 hr) or IV ganciclovir (5
mg/kg every 12hr) are recommended as first-line treatment. Renal function should be moni‐
tored frequently during treatment, with estimated or measured glomerular filtration rate.
Optimal length of treatment should be achieved by monitoring weekly viral loads and treating
until one or two consecutive negative samples are obtained, but not shorter than 2 weeks.
Duration should reflect the likelihood of recurrent CMV infection. In cases of serious disease
and in tissue-invasive disease without viremia, longer treatment periods with clinical moni‐
toring of the specific disease manifestation are recommended. In cases of recurrent CMV
disease, prophylaxis after retreatment may need to be prolonged. [44].
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8. Transplantation
CMV seroprevalence is high in developing countries such as Brazil, so most of the patients
and/or donors is CMV IgG positive. The techniques chosen for the laboratorial monitoring in
our service after liver transplantation are antigenemia and Nested-PCR (N-PCR). These
techniques detect the active viral replication and minimize the damage of the disease caused
by CMV (see Section xy).
We diagnose active infection from one positive result by antigenemia, or two positive N-PCR
findings over an interval equal or smaller than 30 days. As antigenemia can detect CMV a few
days to one week before the appearance of the symptoms, the Ganciclovir is initiated after the
detection of a positive cell even without clinical symptoms if the patient presents IgG negative
and the donor presents IgG positive. Patients are monitored while in hospital and after
discharge following a protocol: weekly from the first to the second month, fortnightly in the
third-fourth months and monthly until six months. After this period the antigenemia or N-
PCR is performed only if there is a suggestive clinical diagnosis of CMV infection. The
assessment of antigenemia also provides an estimate of viral load that is useful in the differ‐
entiation of CMV disease from other complications. Thus we evaluate the efficacy of antiviral
therapy and have capacity to detect drug resistance.
CMV is frequently detected in our patients after liver transplantation [24,25,30,31]. Detection
of N-PCR and antigenemia are useful markers for active infection [30,31].The rates of CMV
found in our groups are similar to other services [24,25,30-32].
We also observed that symptomatic CMV infection occurs during the first three months after
transplantation. We consider that this high incidence of symptomatic CMV infection is due to
the high prevalence of the virus in Brazilian population. The mean time for initial detection
CMV is around 29 days following transplantation (range: 0-99 days) [30]..
In our service, CMV DNA diagnosed in pretransplantation graft biopsy specimens remained
positive posttransplantation on graft biopsies. This common complication negatively influen‐
ces liver transplantation outcomes and is a risk factor to develop acute cellular rejection
episodes [67].Ganciclovir prophylaxis for CMV is not performed at our institution unless the
patient is preoperative negative IgG and the donor is CMV positive. Prophylaxis is performed
only for herpes simplex type 1 with Acyclovir.
Another relevant issue at our service is opportunistic infections, which are often seen in
patients at risk for CMV and have been recognized by our staff as a significant risk factor for
graft failure and death [24]. Active CMV infection may increase the risk of bacterial, fungal,
viral, and others, as well as post-transplant lymphoproliferative disease. [31] This includes co-
infections by other viruses of the same family (HHV-6, HHV-7) [24,32].
The clinical impact of CMV-infected patients observed by our team [24] shows that it is
extremely important to follow up these patients. These data have helped the medical staff
making therapeutic strategies to minimize risks caused by this betaherpesvirus.
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Figure 1. Nuclei of neutrophils stained in brown indicating positive pp65-atigenemia (counterstained with Harris’s
hematoxylin). Mouse C10 and C11 monoclonal antibodies against pp65-matrix CMV antigen and rabbit anti-mouse Ig
horseradish peroxidase conjugate. The reaction was revealed by hydrogen peroxide and amino-ethyl-carbazole24
Virus Synonym Subfamily Abbreviation
Human Herpesvirus-1 Herpes simplex-1 || HSV-1/HHV-1
Human Herpesvirus -2 Herpes simplex-2 || HSV-2/HHV-2
Human Herpesvirus -3 Varicella-zoster || VZV/HHV-3
Human Herpesvirus -4 Epstein-Barr || EBV/HSV-4
Human Herpesvirus -5 Cytomegalovirus || HCMV/CMV/HHV-5
Human Herpesvirus -6 None || HHV-6
Human Herpesvirus -7 None || HHV-7
Human Herpesvirus -8 None || KSHV/HHV-8
Table 1. Complete list of human herpesvirus
9. Conclusion
Few patients remain free of betaherpesvirus after liver transplantation. Active CMV infection
is common especially in the first weeks after grafting. We believe it is important to continue
monitoring CMV infection after transplantation, especially when the prevalence in the general
population is high.
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